Name | Value |
---|---|
Revenues | 0.0M |
Cost of Revenue | 0.0M |
Gross Profit | 0.0M |
Operating Expense | 13.6M |
Operating I/L | -13.6M |
Other Income/Expense | 0.5M |
Interest Income | 0.6M |
Pretax | -13.1M |
Income Tax Expense | -0.5M |
Net Income/Loss | -12.5M |
Neoleukin Therapeutics, Inc. is a biopharmaceutical company specializing in developing immunotherapies for cancer, inflammation, and autoimmunity disorders through protein design technology. Their lead product candidate, NL-201, is a de novo protein designed to replicate the therapeutic activity of cytokines interleukin (IL)-2/IL-15 for treating various cancers, including renal cell carcinoma and melanoma.